Judge Approves $10.8 Million Settlement Deal in BMS Class Action Lawsuit

A federal judge in California signed off on a $10.8 million settlement by Bristol Myers Squibb (BMS) in a lawsuit over for an alleged anticompetitive scheme involving human immunodeficiency virus (HIV) drugs.

The settlement resolves the complaint by KPH Healthcare Services, also known as Kinney Drugs, filed against BMS, its subsidiary E.R. Squibb and Sons and Gilead Sciences.

Under the terms of the class action settlement, BMS is also expected to pay up to $200,000 to notify the relevant class members of the proposed settlement.

The settlement also prevents BMS from restricting Gilead Sciences from making or licensing a generic version of Evotaz (atazanavir and cobicistat), an HIV drug.